RESUMEN
A chronic subdural haematoma (CSDH) is a collection of aged blood between the dura and the brain, typically treated with surgical evacuation. Many patients with CSDH have comorbidities requiring the use of antithrombotic medications. The optimal management of these medications in the context of CSDH remains unknown, as the risk of recurrence must be carefully weighed against the risk of vaso-occlusive events. To better understand these risks and inform the development of clinical practice guidelines, we conducted a systematic review and meta-analysis. A systematic review was conducted in accordance with the PRISMA guidelines, searching Medline and Embase databases. The study was registered with PROSPERO (CRD42023397061). A total of 44 studies were included, encompassing 1 prospective cohort study and 43 retrospective cohort studies. Pooled odds ratios (ORs) were calculated for CSDH recurrence and vaso-occlusive events in patients taking anticoagulant or antiplatelet medications compared to patients not receiving antithrombotic therapy. GRADE was used to assess the quality of evidence. In patients on anticoagulant therapy at CSDH diagnosis, the pooled OR for CSDH recurrence was 1.41 (95% CI 1.11 to 1.79; I2 = 28%). For patients on antiplatelet therapy, the pooled OR was 1.31 (95% CI 1.08 to 1.58; I2 = 32%). Patients taking antithrombotic medications had a significantly higher risk of vaso-occlusive events, with a pooled OR of 3.74 (95% CI 2.12 to 6.60; I2 = 0%). There was insufficient evidence to assess the impact of time to recommence antithrombotic medication on CSDH outcomes. We found that baseline antithrombotic use is associated with the risk of CSDH recurrence and vaso-occlusive events following surgical evacuation. The evidence base is of low quality, and decisions regarding antithrombotic therapy should be individualised for each patient. Further high-quality, prospective studies or registry-based designs are needed to better inform clinical decision-making and establish evidence-based guidelines.
RESUMEN
Anaemia is a condition in which the number of red cells necessary to meet the body's physiological requirements is insufficient. Iron deficiency anaemia and the anaemia of chronic disease are the two most common causes of anaemia worldwide;1 iron homeostasis plays a pivotal role in the pathogenesis of both diseases. An understanding of how iron studies can be used to distinguish between these diseases is therefore essential not only for diagnosis but also in guiding management. This review will primarily focus on iron deficiency anaemia and anaemia of chronic disease; however, iron overload in anaemia will also be briefly discussed.
Asunto(s)
Anemia Ferropénica/metabolismo , Ferritinas/metabolismo , Sobrecarga de Hierro/metabolismo , Hierro/metabolismo , Anemia Ferropénica/diagnóstico , Anemia Ferropénica/patología , Anemia Ferropénica/terapia , Enfermedad Crónica , Manejo de la Enfermedad , Eritrocitos/metabolismo , Eritrocitos/patología , Ferritinas/genética , Regulación de la Expresión Génica , Hepcidinas/genética , Hepcidinas/metabolismo , Homeostasis , Humanos , Hierro/administración & dosificación , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/patología , Sobrecarga de Hierro/terapia , Protoporfirinas/metabolismo , Receptores de Transferrina/genética , Receptores de Transferrina/metabolismo , Transferrina/genética , Transferrina/metabolismoRESUMEN
Being overweight or obese is associated with a higher individual risk of venous thromboembolism and poorer postprocedural outcomes after hip or knee replacement surgery. In addition, there is evidence that obesity represents a significant driving factor for the current and projected prevalence of atrial fibrillation. Rivaroxaban and other direct oral anticoagulants offer fixed-dose regimens for these indications. They do not require therapeutic drug monitoring or dose adjustment according to the weight of the patient. However, primary care physicians seem to be hesitant to accept the concept of a fixed-dose regimen for patients at extremes of weight, perhaps because of familiarity with weight-based dosing of other drugs including low molecular weight heparins. The main concerns related to unadjusted dosing are increased exposure in underweight patients leading to a risk of excessive bleeding and conversely to underanticoagulation of overweight patients. Rivaroxaban has shown similar efficacy and a similar or better safety profile compared with standard treatment for several venous and arterial indications, including venous thromboembolism, nonvalvular atrial fibrillation, and acute coronary syndrome. Prespecified subgroup analyses of patients stratified by weight or body mass index demonstrated outcomes that were consistent with the overall analysis and within each weight and body mass index group. The results suggest that standard-dose rivaroxaban can be safely prescribed in adult patients of all weights.
Asunto(s)
Inhibidores del Factor Xa/administración & dosificación , Rivaroxabán/administración & dosificación , Índice de Masa Corporal , Peso Corporal , Ensayos Clínicos Fase III como Asunto , Inhibidores del Factor Xa/efectos adversos , Humanos , Rivaroxabán/efectos adversosAsunto(s)
Anemia Megaloblástica/sangre , Eritropoyesis , Deficiencias de Hierro , Hierro/sangre , Adulto , Anemia Megaloblástica/tratamiento farmacológico , Eritropoyesis/efectos de los fármacos , Femenino , Ferritinas/sangre , Ácido Fólico/uso terapéutico , Hemoglobinas/análisis , Humanos , Vitamina B 12/sangreAsunto(s)
Leucemia-Linfoma de Células T del Adulto/diagnóstico , Linfocitos/patología , Núcleo Celular/ultraestructura , Forma del Núcleo Celular , Estreñimiento/sangre , Estreñimiento/patología , Citodiagnóstico , Femenino , Humanos , Letargia/sangre , Letargia/patología , Leucemia-Linfoma de Células T del Adulto/sangre , Leucemia-Linfoma de Células T del Adulto/patología , Leucemia-Linfoma de Células T del Adulto/fisiopatología , Linfocitos/ultraestructura , Persona de Mediana Edad , Náusea/sangre , Náusea/patología , Manejo de Especímenes , Vómitos/sangre , Vómitos/patologíaRESUMEN
An elderly man presented with a macrocytic anemia with severe reticulocytopenia. The observation of trilineage dysplasia in addition to red cell aplasia led to a diagnosis.
Asunto(s)
Síndromes Mielodisplásicos/diagnóstico , Aplasia Pura de Células Rojas/diagnóstico , Anciano , Anemia Macrocítica , Examen de la Médula Ósea , Pruebas Hematológicas , Humanos , Masculino , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/patología , Prednisolona/uso terapéutico , Aplasia Pura de Células Rojas/etiología , Aplasia Pura de Células Rojas/patologíaRESUMEN
Factor X is one of the vitamin K-dependent serine proteases. It plays a crucial role in the coagulation cascade, as the first enzyme in the common pathway of thrombus formation. The gene for factor X maps to the long arm of chromosome 13, approximately 2.8 kb downstream of the factor VII gene. The gene consists of eight exons, each of which encodes a specific functional domain within the protein. Both the gene structure and the amino acid sequence show homology to other vitamin K-dependent clotting factors, suggesting their origin in a common ancestral protein. Factor X deficiency is one of the rarest of the inherited coagulation disorders. Inheritance is in an autosomal recessive manner. The clinical phenotype is of a variable bleeding tendency. Homozygous factor X deficiency has an incidence of 1:1,000,000 in the general population. Heterozygotes are often clinically asymptomatic. Acquired factor X deficiency is rare, but when it occurs it is usually in association with amyloidosis. Treatment of factor X deficiency involves replacement of the protein with either fresh frozen plasma or prothrombin complex concentrates, although the latter should be used with caution as infusion may be associated with an increased risk of thrombosis.